Back

Becton Dickinson and Company

Ticker: BDX ISIN: US0758871091
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer
Market cap
$58.89B
P/E
34.47
Forward P/E
14.62
Profit margin
8.37%
Revenue growth QoQ
9.80%
Div. yield
1.95%
Beta
0.38
$189.78 -0.50%
Price as of 2026-08-25 · NYSE

Performance by timeframe

Rolling returns
1 Month +19.42%
6 Months +6.29%
1 Year +27.44%
5 Years +1.67% p.a.+8.63%
10 Years +5.02% p.a.+63.09%
Since inception +9.73% p.a.+916.71%
Calendar year returns
YTD +26.07%
2025 -12.61%
2024 -5.38%
2023 -2.67%
2022 +5.08%
2021 +1.88%

Key stats

Market cap
58.89B
P/E
34.47
Dividend yield
1.95%
Beta
0.38
52-week range
193.03 - 250.85
50-day MA
219.79
200-day MA
230.24
Section 1

Business overview

Company profile data from fundamentals.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector Healthcare
Industry Medical Instruments & Supplies
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 6.84%
ROA 3.70%
Profit margin 8.37%
Operating margin 15.27%
PEG ratio 0.94
Revenue/share TTM 71.27
Revenue TTM 20.64B
EBITDA 5.50B
Gross profit TTM 9.55B
Beta 0.38

Valuation

Trailing P/E 34.47
Forward P/E 14.62
P/B 2.34
P/S 2.85
EV/EBITDA 15.84
EV/Revenue 3.73

ESG Scores

Total ESG 33.8
Environment 4.9
Social 20.1
Governance 13.8
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 14.37
Quarterly earnings growth 8.30%
Revenue TTM 20.64B
Reported quarters 123
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 1.95%
Forward annual div. yield 1.95%
Dividend per share 3.8900
Payout ratio 28.61%
Ex-dividend date 2025-03-10
Split factor 1025:1000
Last split date 2022-04-01
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $275.03
Analyst rating 4.2353

Ownership & short interest

Shares outstanding 287.14M
Shares float 286.45M
Institutional ownership 93.86%
Insider ownership 55.90%
Short ratio 1.88
Short % of float 1.32%

Details

Instrument metadata and source update timestamps.

Symbol BDX
Name Becton Dickinson and Company
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US0758871091
Country USA
Code + exchange BDX.NYSE
Last price date 2025-04-25
Fundamentals updated 2025-04-26

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.